Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis

Fig. 5

Representative images of Hematoxylin & Eosin (H&E) staining of lung tissue from every group indicating less fibrosis severity in pembrolizumab treated animals (Panel A). NO, L and H stand for no pembrolizumab, low-dose pembrolizumab and high-dose pembrolizumab, respectively. Ashcroft score for all groups estimated by H&E images. Bleomycin-treated mice and mice treated with bleomycin and high dose pembrolizumab had significantly higher Ashcroft score compared to saline-treated mice (Kruskal–Wallis test; saline vs. bleomycin: p < 0.001, saline vs. high dose pembrolizumab: p = 0.006). Mice treated with bleomycin and either low or high dose pembrolizumab had significantly lower Ashcroft score compared to bleomycin-treated mice (Kruskal–Wallis test; bleomycin vs. bleomycin and low dose pembrolizumab: p < 0.001, bleomycin vs. bleomycin and high dose pembrolizumab: p = 0.002) (Panel B)

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us